17 results on '"Villanueva, Vicente"'
Search Results
2. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.
- Author
-
Szaflarski, Jerzy P., Besson, Hervé, D'Souza, Wendyl, Faught, Edward, Klein, Pavel, Reuber, Markus, Rosenow, Felix, Salas-Puig, Javier, Soto Insuga, Victor, Steinhoff, Bernhard J., Strzelczyk, Adam, Bourikas, Dimitrios, Daniels, Tony, Floricel, Florin, Friesen, David, Laloyaux, Cédric, and Villanueva, Vicente
- Subjects
PEOPLE with epilepsy ,ETIOLOGY of diseases ,LEARNING disabilities ,COMORBIDITY ,EPILEPSY - Abstract
Objective: To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. Methods: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor−related epilepsy [BTRE], and traumatic brain injury−related epilepsy [TBIE]). Results: At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively. Conclusions: BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.
- Author
-
Toledano, Rafael, Villanueva, Vicente, Toledo, Manuel, Sabaniego, Joel, and Pérez-Domper, Paloma
- Subjects
- *
EPILEPSY , *ECONOMIC impact , *SICK leave , *DATABASES , *PEOPLE with epilepsy , *BRAIN diseases - Abstract
Background: Epilepsy is a chronic brain disease characterized by recurrent seizures. We investigated real-world management of epilepsy across treatment lines in Spain, including healthcare resource use (HRU) and associated costs. Methods: This was a retrospective study of real-life data from epilepsy patients prescribed antiseizure medication (ASM) between January 2016 and December 2021. Patients were grouped according to their line of treatment (1st, 2nd, 3rd and 4th +) during the recruitment period. Demographic and clinical characteristics, comorbidities and concomitant medications were analyzed during the baseline period (6 months before starting treatment line); antiepileptic treatments, concomitant medications, HRU and associated costs were analyzed during follow-up. Results: The study included 5006 patients. Treatment duration decreased as treatment lines progressed (mean ± SD progression time: 523.2 ± 279.1 days from 1st to 2nd line, 351.6 ± 194.4 days from 2nd to 3rd line; 272.7 ± 139.3 days from 3rd to 4th + line). Significant HRU differences were found with subsequent treatment lines, including an increase in hospital admissions and patients on sick leave. Mean (95% CI) adjusted total costs per patient were €2974/year (2773–3175) in the 1st line and €5735/year (5043–6428) in the 4th + line. There was an increase in adjusted direct and total costs with subsequent treatment lines; the mean difference in total costs between cohorts was €2761 (p < 0.001). The highest direct costs were associated with epilepsy medication, days at the hospital and specialist visits. Conclusion: Our data revealed a progressive increase in the use of resources and associated costs across subsequent epilepsy treatment lines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
- Author
-
Villanueva, Vicente, Laloyaux, Cédric, D'Souza, Wendyl, Faught, Edward, Klein, Pavel, Reuber, Markus, Rosenow, Felix, Salas-Puig, Javier, Insuga, Victor Soto, Strzelczyk, Adam, Szaflarski, Jerzy P., Chinn, Chris, Daniels, Tony, Floricel, Florin, Friesen, David, Sendersky, Veronica, Besson, Hervé, and Steinhoff, Bernhard J.
- Subjects
- *
MEDICAL records , *LITERATURE reviews , *SEIZURES (Medicine) , *PEOPLE with epilepsy , *DESCRIPTIVE statistics - Abstract
Background and Objective: Real-world evidence studies of brivaracetam (BRV) have been restricted in scope, location, and patient numbers. The objective of this pooled analysis was to assess effectiveness and tolerability of brivaracetam (BRV) in routine practice in a large international population. Methods: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from multiple independent non-interventional studies of patients with epilepsy initiating BRV in Australia, Europe, and the United States. Eligible study cohorts were identified via a literature review and engagement with country lead investigators, clinical experts, and local UCB Pharma scientific/medical teams. Included patients initiated BRV no earlier than January 2016 and no later than December 2019, and had ≥ 6 months of follow-up data. The databases for each cohort were reformatted and standardised to ensure information collected was consistent. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within 3 months before timepoint), continuous seizure freedom (no seizures from baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Patients with missing data after BRV discontinuation were considered non-responders/not seizure free. Analyses were performed for all adult patients (≥ 16 years), and for subgroups by seizure type recorded at baseline; by number of prior antiseizure medications (ASMs) at index; by use of BRV as monotherapy versus polytherapy at index; for patients who switched from levetiracetam to BRV versus patients who switched from other ASMs to BRV; and for patients with focal-onset seizures and a BRV dose of ≤ 200 mg/day used as add-on at index. Analysis populations included the full analysis set (FAS; all patients who received at least one BRV dose and had seizure type and age documented at baseline) and the modified FAS (all FAS patients who had at least one seizure recorded during baseline). The FAS was used for all outcomes other than ≥ 50% seizure reduction. All outcomes were summarised using descriptive statistics. Results: Analyses included 1644 adults. At baseline, 72.0% were 16–49 years of age and 92.2% had focal-onset seizures. Patients had a median (Q1, Q3) of 5.0 (2.0, 8.0) prior antiseizure medications at index. At 3, 6, and 12 months, respectively, ≥ 50% seizure reduction was achieved by 32.1% (n = 619), 36.7% (n = 867), and 36.9% (n = 822) of patients; seizure freedom rates were 22.4% (n = 923), 17.9% (n = 1165), and 14.9% (n = 1111); and continuous seizure freedom rates were 22.4% (n = 923), 15.7% (n = 1165), and 11.7% (n = 1111). During the whole study follow-up, 551/1639 (33.6%) patients discontinued BRV. TEAEs since prior visit were reported in 25.6% (n = 1542), 14.2% (n = 1376), and 9.3% (n = 1232) of patients at 3, 6, and 12 months, respectively. Conclusions: This pooled analysis using data from a variety of real-world settings suggests BRV is effective and well tolerated in routine clinical practice in a highly drug-resistant patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Proposed Recommendations for the Management of Depression in Adults with Epilepsy: An Expert Consensus.
- Author
-
Villanueva, Vicente, Artal, Jesús, Cabeza-Alvarez, Clara-Isabel, Campos, Dulce, Castillo, Ascensión, Flórez, Gerardo, Franco-Martin, Manuel, García-Portilla, María Paz, Giráldez, Beatriz G., Gotor, Francisco, Gutiérrez-Rojas, Luis, Albanell, Albert Molins, Paniagua, Gonzalo, Pintor, Luis, Poza, Juan José, Rubio-Granero, Teresa, Toledo, Manuel, Tortosa-Conesa, Diego, Rodríguez-Uranga, Juan, and Bobes, Julio
- Subjects
- *
MEDICAL personnel , *SUICIDE risk factors , *PEOPLE with mental illness , *ADULTS , *MENTAL depression , *PRENATAL depression - Abstract
Introduction: Experts agree that there is a need for protocols to guide health professionals on how to best manage psychiatric comorbidities in patients with epilepsy (PWE). We aimed to develop practical recommendations for key issues in the management of depression in PWE. Methods: This was a qualitative study conducted in four steps: (1) development of a questionnaire on the management of depression in PWE to be answered; (2) literature review and, if evidence from guidelines/consensus or systematic reviews was available, drafting initial recommendations; (3) a nominal group methodology for reviewing initial recommendations and formulating new recommendations on those issues without available evidence; and (4) drafting and approving the final recommendations. A scientific committee (one neurologist and one psychiatrist) was responsible for the development of the project and its scientific integrity. The scientific committee selected a panel of experts (nine neurologists and nine psychiatrists with experience in this field) to be involved in the nominal group meetings and to formulate final recommendations. Results: Fifteen recommendations were formulated. Four on the screening and diagnosis: screening and diagnosis of depression, evaluation of the risk of suicide, and diagnosis of depression secondary to epilepsy; nine on the management of depression: referral to a psychiatrist, selection of the antiseizure medication, change of antiseizure medication, antidepressant treatment initiation, selection of antidepressant, use of antidepressants during pregnancy, use of psychotherapy, antidepressant treatment duration, and discontinuation of antidepressant treatment; two on the follow-up: duration of the follow-up under usual conditions, and follow-up of patients at risk of suicide. Conclusion: We provide recommendations based on expert opinion consensus to help healthcare professionals assess depression in PWE. The detection and treatment of major depressive disorders are key factors in improving epilepsy outcomes and avoiding suicide risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The relationship between memory and quality of life is mediated by trait anxiety in patients with temporal lobe epilepsy.
- Author
-
Cano-López, Irene, Lozano-García, Alejandro, Catalán-Aguilar, Judit, Hampel, Kevin G., Villanueva, Vicente, and González-Bono, Esperanza
- Subjects
QUALITY of life ,MEDICAL care ,HEALTH outcome assessment ,EPILEPSY ,DECISION making - Abstract
Purpose: Memory deficits are very frequent in patients with drug-resistant epilepsy, but they predict a small proportion of variance of their quality of life (QOL) in previous studies, possibly due to the lack of consideration of mediating factors of this relationship. This study aimed to examine whether trait anxiety mediates the relationship between memory and QOL in this population, controlling the influence of demographic and seizure-related factors. Methods: In this cross-sectional study, 119 adults with drug-resistant temporal lobe epilepsy (TLE) underwent a neuropsychological evaluation, in which memory, anxiety, and QOL were assessed. Results: In the total sample, better delayed memory had an effect on better QOL indirectly through lower trait anxiety (B = 0.13, SE = 0.06, p = 0.04, ab
cs = 0.13; κ2 = 0.18; PMind = 0.76). Additionally, delayed memory has not a direct association with QOL (B = 0.04, SE = 0.09, p = 0.64, Cohen's f2 = 0.005; PMdir = 0.24), and the total effect of delayed memory on QOL tended to reach statistical significance (B = 0.17, SE = 0.10, p = 0.08). The proposed mediation model yielded excellent fit (CFI = 1.00, RMSEA = 0.0001, SRMR = 0.009, and χ2 (1) = 0.50, p = 0.48) and explained 38% of the variance of QOL. Conclusion: These findings suggest that trait anxiety is an important factor in understanding the relationship between memory and QOL in patients with TLE, considering the influence of demographic and seizure-related variables, and may have relevant implications for decision-making in this population. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
7. Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain.
- Author
-
Gil-Nagel, Antonio, Sánchez-Carpintero, Rocío, and Villanueva, Vicente
- Subjects
QUALITY of life ,MENTAL illness ,STATUS epilepticus ,GENETIC mutation - Abstract
The aim of this study was to describe the profile of patients diagnosed with Dravet syndrome (DS), their clinical management, and the impact of DS on their quality of life (QoL) and family. Data of 80 patients from 11 centres in Spain was collected. Patients (47.5% female) were 12.7 (9.6) years on average (SD, standard deviation). Despite the first episode occurred when patients were a mean (SD) of 0.4 (0.2) years, DS was not diagnosed until they were 6.9 (10.1) years old. The majority (86.7%) had SCN1A gene mutations and 73.4% had seizures during the last year (mostly generalized motor seizures [47.8%]). The mean (SD) number of status epilepticus episodes was 3.6 (8.0) since diagnosis and 0.1 (0.5) in the last year. On the Health Utilities Index Mark (HUI) multi-attribute scale, the mean global score (SD) was 0.56 (0.24) in HUI2 and 0.32 (0.37) in HUI3. The impact of the disease was severe in most patients (HUI2, 81%; HUI3, 83.5%). In the Care-related QoL (CarerQol) the mean (SD) well-being score was 7.2 (2.1). Most caregivers (90%) were satisfied with their caregiving tasks, although 75% had difficulties combining these tasks with daily activities, 68.8% reported mental health problems and 61.2% physical problems. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Antiseizure medications (antiepileptic drugs) in adults: starting, monitoring and stopping.
- Author
-
Angus-Leppan, Heather, Sperling, Michael R., and Villanueva, Vicente
- Subjects
EPILEPSY ,ANTICONVULSANTS ,DRUG monitoring ,DRUGS ,ADULTS ,DIAGNOSIS of epilepsy - Abstract
Up to 10% of people living to 80 years of age have one or more seizures; and many will not require anti-seizure medication (ASMs). In 85% of patients, the diagnosis comes from the history of the index event. One-third of patients with an apparent "first seizure" have previous events, changing their diagnosis to epilepsy. Targeted investigations are important for classification and risk prediction. Patients with a low risk of seizure recurrence are not usually offered ASM treatment. High-risk patients have multiple seizures, neurological deficits, intellectual disability and/or relevant abnormal investigations; and are offered ASMs. Individual factors modulate this decision-making. Future integrated technologies offer the game-changing potential for seizure monitoring and prediction, but are not yet robust, convenient or affordable. Therapeutic drug monitoring in patients taking ASMs may confirm ASM toxicity, or when non-adherence, malabsorption, or rapid metabolism are suspected causes of breakthrough seizures. They are less useful when these factors are intermittent or irregular. Current evidence does not favour routine monitoring of serum levels, as it neither reliably predicts control, relapse, or adverse effects. The decision to discontinue ASM should follow a full discussion with the patient of risks and benefits. Along with population risk factors for seizure recurrence, the patient's lifestyle and preferences must be considered. ASM are usually discontinued in a slow step-wise fashion, one at a time, after at least two years of remission. Seizure recurrence risk plateaus only after 2 years following ASM discontinuation, and patients need access to specialist follow-up over that period. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
- Author
-
Villanueva, Vicente, D'Souza, Wendyl, Goji, Hiroko, Kim, Dong Wook, Liguori, Claudio, McMurray, Rob, Najm, Imad, Santamarina, Estevo, Steinhoff, Bernhard J., Vlasov, Pavel, Wu, Tony, and Trinka, Eugen
- Subjects
- *
PERAMPANEL , *GLOBAL analysis (Mathematics) , *STATUS epilepticus , *PEOPLE with epilepsy , *RF values (Chromatography) - Abstract
The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study was a pooled analysis of data from 44 real-world studies from 17 countries, in which people with epilepsy (PWE; focal and generalized) were treated with perampanel (PER). Retention and effectiveness were assessed after 3, 6, and 12 months, and at the last visit (last observation carried forward). Effectiveness assessments included 50% responder rate (≥ 50% reduction in seizure frequency from baseline) and seizure freedom rate (no seizures since at least the prior visit); in PWE with status epilepticus, response was defined as seizures under control. Safety and tolerability were assessed by evaluating adverse events (AEs) and discontinuation due to AEs. The Full Analysis Set included 5193 PWE. Retention, effectiveness and safety/tolerability were assessed in 4721, 4392 and 4617, respectively. Retention on PER treatment at 3, 6, and 12 months was 90.5%, 79.8%, and 64.2%, respectively. Mean retention time on PER treatment was 10.8 months. The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, and the corresponding seizure freedom rates were 23.2% and 20.5%, respectively; 52.7% of PWE with status epilepticus responded to PER treatment. Overall, 49.9% of PWE reported AEs and the most frequently reported AEs (≥ 5% of PWE) were dizziness/vertigo (15.2%), somnolence (10.6%), irritability (8.4%), and behavioral disorders (5.4%). At 12 months, 17.6% of PWEs had discontinued due to AEs. PERMIT demonstrated that PER is effective and generally well tolerated when used to treat people with focal and/or generalized epilepsy in everyday clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥ 60 Versus < 60 Years: A Subanalysis from the Euro-Esli Study.
- Author
-
Lawthom, Charlotte, Bermejo, Pedro, Campos, Dulce, McMurray, Rob, and Villanueva, Vicente
- Published
- 2019
- Full Text
- View/download PDF
11. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
- Author
-
Lawthom, Charlotte, Peltola, Jukka, McMurray, Rob, Dodd, Emma, and Villanueva, Vicente
- Published
- 2018
- Full Text
- View/download PDF
12. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.
- Author
-
Villanueva, Vicente, Holtkamp, Martin, Delanty, Norman, Rodriguez-Uranga, Juan, McMurray, Rob, and Santagueda, Patricia
- Subjects
- *
ANTICONVULSANTS , *SEIZURES (Medicine) , *DRUG efficacy , *DRUG side effects , *SODIUM channel blockers , *THERAPEUTICS - Abstract
The Euro-Esli study was an exploratory pooled analysis of data from 14 European clinical practice studies, which was conducted to audit the real-world effectiveness, safety, and tolerability of eslicarbazepine acetate (ESL) as an adjunctive treatment for partial-onset seizures. Retention and effectiveness were assessed after 3, 6, and 12 months of ESL treatment, and at the final visit. Safety and tolerability were assessed throughout ESL treatment by evaluating adverse events (AEs) and ESL discontinuation due to AEs. Data from 2058 patients (52.1% male; mean age 44.0 years) were included. All 2058 patients were assessed for safety and 1975 (96.0%) patients were assessed for effectiveness. After 12 months, retention, responder (≥50% seizure frequency reduction), and seizure freedom rates were 73.4, 75.6, and 41.3%, respectively. AEs were reported for 34.0% of patients and led to discontinuation in 13.6% of patients. The most frequently reported AEs were dizziness (6.7% of patients), fatigue (5.4%), and somnolence (5.1%). No unexpected safety signals emerged over a median duration of follow-up of >5 years. Subgroup analyses revealed that ESL was significantly more effective in patients aged ≥65 versus <65 years, in patients who were not receiving treatment with other sodium channel blockers versus those who were receiving treatment with other sodium channel blockers, and in patients who were receiving <2 versus ≥2 concomitant antiepileptic drugs at baseline. Euro-Esli is the largest ESL clinical practice study conducted to date. This study provides strong and reassuring evidence of ESL's safety profile, and complements the data from clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study.
- Author
-
Villanueva, Vicente, Garcés, Mercedes, López-Gomáriz, Elena, Serratosa, José, González-Giráldez, Beatriz, Parra, Jaime, Rodríguez-Uranga, Juan, Toledo, Manuel, López González, Francisco, Bermejo, Pedro, Giner, Pau, Castillo, Ascensión, Molins, Albert, Campos, Dulce, Mauri, José, Muñoz, Rosario, Bonet, Macarena, Serrano-Castro, Pedro, Villar, Ana, and Saiz-Díaz, Rosa
- Subjects
- *
TREATMENT of epilepsy , *VIMPAT , *ANTICONVULSANTS , *DRUG efficacy , *SPASMS , *MEDICAL records , *RETROSPECTIVE studies - Abstract
Background and objectives: Many patients with epilepsy are treated with antiepileptic drug (AED) polytherapy. Several factors influence the choice of early add-on therapy, and deciding on the most appropriate drug can be difficult. This study aimed to assess the efficacy and tolerability of lacosamide as early add-on therapy in patients with partial-onset seizures. Methods: REALLY (REtrospective study of lAcosamide as earLy add-on aLong one Year) was a multicenter, retrospective, 1-year, real-life study. Patients included were aged older than 16 years, had partial-onset seizures, and were treated with lacosamide as add-on therapy after one or two prior AEDs. Data were collected retrospectively from clinical records. The primary study objective was to assess the efficacy of lacosamide over 12 months (seizure-free and responder rates), and the secondary objective was to assess the tolerability of lacosamide at 3, 6, and 12 months [adverse events (AEs) and discontinuation]. Results: One hundred and ninety-nine patients were enrolled in the study; 89 patients (44.7 %) had tried one AED and 110 patients (55.3 %) had tried two AEDs before lacosamide. At 12 months, the proportion of patients who were seizure free was 44.9 %, and 76 % of patients were responders. The seizure-free rate at 12 months for patients who had previously received one or two AEDs was 58 and 34.3 %, and the responder rate at 12 months was 83.0 and 70.4 %, respectively. The AE rate was 21.5 % at 3 months, 27.1 % at 6 months, and 31.2 % at 12 months, with 7.0 % of patients discontinuing treatment because of an AE. The most common AE reported was dizziness (11.6 %). Cryptogenic epilepsy, a higher number of prior AEDs, and the use of a sodium channel blocker at onset were associated with a worse outcome. The number of concomitant AEDs decreased over 1 year ( Z = 5.89; p < 0.001). Twenty-two patients were converted to lacosamide monotherapy with at least one evaluation ≥6 months from the beginning of monotherapy conversion. Conclusions: Lacosamide was effective and well tolerated as early add-on treatment in patients who had received one or two previous AEDs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. The sentence verification task: a reliable fMRI protocol for mapping receptive language in individual subjects.
- Author
-
Sanjuán A, Forn C, Ventura-Campos N, Rodríguez-Pujadas A, García-Porcar M, Belloch V, Villanueva V, Avila C, Sanjuán, Ana, Forn, Cristina, Ventura-Campos, Noelia, Rodríguez-Pujadas, Aina, García-Porcar, María, Belloch, Vicente, Villanueva, Vicente, and Avila, César
- Abstract
Objective: To test the capacity of a sentence verification (SV) task to reliably activate receptive language areas. Presurgical evaluation of language is useful in predicting postsurgical deficits in patients who are candidates for neurosurgery. Productive language tasks have been successfully elaborated, but more conflicting results have been found in receptive language mapping.Materials and Methods: Twenty-two right-handed healthy controls made true-false semantic judgements of brief sentences presented auditorily.Results: Group maps showed reliable functional activations in the frontal and temporoparietal language areas. At the individual level, the SV task showed activation located in receptive language areas in 100% of the participants with strong left-sided distributions (mean lateralisation index of 69.27).Conclusion: The SV task can be considered a useful tool in evaluating receptive language function in individual subjects. This study is a first step towards designing the fMRI task which may serve to presurgically map receptive language functions. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
15. Comparison of two fMRI tasks for the evaluation of the expressive language function.
- Author
-
Sanjuán, Ana, Bustamante, Juan-Carlos, Forn, Cristina, Ventura-Campos, Noelia, Barrós-Loscertales, Alfonso, Martínez, Juan-Carlos, Villanueva, Vicente, and Ávila, César
- Subjects
NEUROSURGERY complications ,EXPRESSIVE language ,BRAIN diseases ,PEOPLE with epilepsy ,TEMPORAL lobe epilepsy ,GLIOMAS ,COGNITIVE processing of language ,PHYSIOLOGY ,MAGNETIC resonance imaging ,PATIENTS - Abstract
Presurgical evaluation of language is important in patients who are candidates for neurosurgery since language decline is a frequent complication after an operation. Different functional magnetic resonance imaging (fMRI) tasks, such as the verb generation task (VGT) and the verbal fluency task (VFT) have been employed. Our objective was to compare how effective these tasks are at evaluating language functioning in controls (study 1) and patients (study 2). Eighteen controls and 58 patient candidates for neurosurgery (16 patients with temporal lobe epilepsy and 42 patients with brain lesions: 11 astrocytomas, six cavernomas, 14 gliomas, four AVM and seven meningiomas) were recruited in order to compare the activation patterns of language areas as determined by the VGT and VFT. In both samples, the VGT produced a more specific activation of left Broca’s area. In contrast, the VFT yielded a wider and more intense activation of the left Broca’s area in controls, as well as other activations in the dorsolateral prefrontal cortex and the striatum. Additionally, both studies showed good agreement on language dominance derived from the tasks, although there was some variability in laterality index scores. Both language tasks are useful in evaluation of expressive language. The VGT is a more specific task, while the VFT is more unspecific but activates language-related areas that are not found with the VGT owing to its phonological component. Therefore, each task contributes to the lateralisation and localisation of expressive language areas with complementary information. The advisability of combining tasks to improve fMRI presurgical evaluation is confirmed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Mesial temporal sclerosis as a complication of hematologic cancer.
- Author
-
Sivera, Rafael, Bataller, Luis, Martínez, Jesús, and Villanueva, Vicente
- Subjects
LETTERS to the editor ,EPILEPSY - Abstract
A letter to the editor is presented which reports on a case of the development of temporal epilepsy due to mesial temporal sclerosis (MTS) in patients with hematologic cancer.
- Published
- 2009
- Full Text
- View/download PDF
17. Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.
- Author
-
Laxer, Kenneth D., Elder, Christopher J., Di Gennaro, Giancarlo, Ferrari, Louis, Krauss, Gregory L., Pellinen, Jacob, Rosenfeld, William E., and Villanueva, Vicente
- Abstract
Cenobamate has demonstrated efficacy in patients with treatment-resistant epilepsy, including patients who continued to have seizures after epilepsy surgery. This article provides recommendations for cenobamate use in patients referred for epilepsy surgery evaluation. A panel of six senior epileptologists from the United States and Europe with experience in presurgical evaluation of patients with epilepsy and in the use of antiseizure medications (ASMs) was convened to provide consensus recommendations for the use of cenobamate in patients referred for epilepsy surgery evaluation. Many patients referred for surgical evaluation may benefit from ASM optimization; both ASM and surgical treatment should be individualized. Based on previous clinical studies and the authors’ clinical experience with cenobamate, a substantial proportion of patients with treatment-resistant epilepsy can become seizure-free with cenobamate. We recommend a cenobamate trial and ASM optimization in parallel with presurgical evaluations. Cenobamate can be started before phase two monitoring, especially in patients who are found to be suboptimal surgery candidates. As neurostimulation therapies are generally palliative, we recommend trying cenobamate before vagus nerve stimulation (VNS), deep brain stimulation, or responsive neurostimulation (RNS). In surgically remediable cases (mesial temporal sclerosis, benign discrete lesion in non-eloquent cortex, cavernous angioma, etc.), cenobamate use should not delay imminent surgery; however, a patient may decide to defer or even cancel surgery should they achieve sustained seizure freedom with cenobamate. This decision should be made on an individual, case-by-case basis based on seizure etiology, patient preferences, potential surgical risks (mortality and morbidity), and likely surgical outcome. The addition of cenobamate after unsuccessful surgery or palliative neuromodulation may also be associated with better outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.